Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,140,196
  • Shares Outstanding, K 256,121
  • Annual Sales, $ 3,048 M
  • Annual Income, $ 2,097 M
  • 60-Month Beta 1.48
  • Price/Sales 15.21
  • Price/Cash Flow 57.38
  • Price/Book 9.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.75
  • Number of Estimates 7
  • High Estimate 0.85
  • Low Estimate 0.71
  • Prior Year 0.62
  • Growth Rate Est. (year over year) +20.97%

Price Performance

See More
Period Period Low Period High Performance
1-Month
165.80 +8.66%
on 06/03/19
186.33 -3.32%
on 06/20/19
+8.38 (+4.88%)
since 05/24/19
3-Month
163.68 +10.06%
on 04/18/19
191.71 -6.03%
on 04/10/19
-3.70 (-2.01%)
since 03/25/19
52-Week
145.37 +23.93%
on 06/28/18
195.81 -8.00%
on 01/22/19
+25.39 (+16.41%)
since 06/25/18

Most Recent Stories

More News
Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children

Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.

ANIK : 38.90 (+0.75%)
MRUS : 13.89 (-1.42%)
VRTX : 179.46 (-0.38%)
ACOR : 7.10 (+0.57%)
FDA Approves SYMDEKO(R) (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

---Vertex's third medicine approved to treat the underlying cause of CF in eligible patients in this age range-

VRTX : 179.46 (-0.38%)
3 Big Biotechs Hold Growth Potential in Second Half of 2019

We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.

CELG : 93.19 (+0.40%)
ARRY : 46.10 (-0.24%)
VRTX : 179.46 (-0.38%)
GILD : 67.73 (-1.10%)
BMY : 45.54 (-0.50%)
ALXN : 125.28 (+0.10%)
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

TECH : 203.98 (+0.27%)
ILMN : 355.89 (-0.61%)
VRTX : 179.46 (-0.38%)
RGEN : 81.10 (+0.78%)
GILD : 67.73 (-1.10%)
5 Biotech Stocks to Buy Right Now

here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.

TECH : 203.98 (+0.27%)
ILMN : 355.89 (-0.61%)
VRTX : 179.46 (-0.38%)
RGEN : 81.10 (+0.78%)
GILD : 67.73 (-1.10%)
Vertex Pharm Set to Possibly Pullback After Yesterday's Rally of 3.11%

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $167.66 to a high of $171.83. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of...

VRTX : 179.46 (-0.38%)
Vertex Selects Triple Combo Regimen for Regulatory Submission

Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

CRSP : 44.30 (+0.73%)
PTI : 1.03 (+0.98%)
VRTX : 179.46 (-0.38%)
ABBV : 67.10 (+2.13%)
Why Is Vertex (VRTX) Down 3.5% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

VRTX : 179.46 (-0.38%)
Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis

---Statistically significant improvements observed in all key secondary endpoints in patients with one F508del mutation and one minimal function mutation, including a 63% reduction in the annualized rate...

VRTX : 179.46 (-0.38%)
Watch for Vertex Pharm to Potentially Rebound After Falling 2.63% Yesterday

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $167.18 to a high of $171.24. Yesterday, the shares fell 2.6%, which took the trading range below the 3-day low of $169.50...

VRTX : 179.46 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 184.52
1st Resistance Point 182.34
Last Price 179.46
1st Support Level 178.73
2nd Support Level 177.30

See More

52-Week High 195.81
Last Price 179.46
Fibonacci 61.8% 176.54
Fibonacci 50% 170.59
Fibonacci 38.2% 164.64
52-Week Low 145.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar